Twist Bioscience Corporation

Twist Bioscience Corporation has been granted 65 US utility patents between 2016 and 2025, placing Twist Bioscience Corporation at rank #5,332 across all assignees tracked by PlainPatent. This portfolio spans 21 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.0 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Twist Bioscience Corporation is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 48.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 51 grants, compared with 14 in the 2015–2019 window — a +264% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Twist Bioscience Corporation's 17.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 21 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Twist Bioscience Corporation against peers pursuing similar technology classes.